Ascendis Pharma AS (ASND)vsMerck & Company Inc (MRK)
ASND
Ascendis Pharma AS
$210.45
-3.83%
HEALTHCARE · Cap: $13.32B
MRK
Merck & Company Inc
$120.79
-2.77%
HEALTHCARE · Cap: $285.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 7496% more annual revenue ($65.77B vs $865.78M). ASND leads profitability with a 57.3% profit margin vs 13.6%. ASND trades at a lower P/E of 24.7x. ASND earns a higher WallStSmart Score of 55/100 (C).
ASND
Buy55
out of 100
Grade: C
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ASND.
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 104 in profit
Keeps 57 of every $100 in revenue as profit
Revenue surging 144.3% year-over-year
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Elevated debt levels
Weak financial health signals
Trading at 23.3x book value
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ASND
The strongest argument for ASND centers on Return on Equity, Profit Margin, Revenue Growth. Profitability is solid with margins at 57.3% and operating margin at 10.1%. Revenue growth of 144.3% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : ASND
The primary concerns for ASND are EPS Growth, Debt/Equity, Piotroski F-Score. Debt-to-equity of 1.84 is elevated, increasing financial risk.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
ASND profiles as a growth stock while MRK is a value play — different risk/reward profiles.
ASND carries more volatility with a beta of 0.48 — expect wider price swings.
ASND is growing revenue faster at 144.3% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
ASND scores higher overall (55/100 vs 50/100), backed by strong 57.3% margins and 144.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ascendis Pharma AS
HEALTHCARE · BIOTECHNOLOGY · USA
Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?